MOLCURE

MOLCURE Inc. is a Japanese AI-powered drug discovery company founded in 2013, focused on accelerating the development of functional antibodies and peptides. Its platform integrates advanced machine learning, next-generation sequencing, bioinformatics, and laboratory robotics to enable true de novo antibody discovery — generating novel, high-affinity candidates without relying on prior experimental data. MOLCURE collaborates with global pharmaceutical partners including Boehringer Ingelheim, and has over 11 years of experience building proprietary antibody data analysis frameworks. The company was co-founded by researchers from Keio University and operates at the intersection of AI, biotech, and drug design.